Evaluate laser acupuncture (LA) as an adjuvant therapy in pain management during percutaneous kidney biopsy procedure in children and adolescents. This prospective, double-blinded, randomized controlled trial enrolled patients aged 7 to 26 years admitted to a children's hospital for percutaneous kidney biopsy. Patients received LA to treatment points (acupuncture group) or sham points (control group) before the procedure. The laser delivered a dose of 42 J/cm 2 over 10 acupoints. Patients and parents rated the pain during and after the biopsy, and change in pain scores were calculated for each patient. Anxiety, vital signs, sedation medication, and patient's biopsy experience were secondary outcomes. Sixty-nine treatments (33 in the acupuncture group and 36 in the control group) were eligible for analysis. Patients in the acupuncture group reported a significantly improved change in the pain score after the biopsy compared with the controls (0.8 vs 20.5, P 5 0.044). Patients in the acupuncture group had a statistically significant decrease in procedure vital signs including heart rate (21.8 vs 5.6, P 5 0.043) and respiratory rate (22.4 vs 0.4, P 5 0.045) when compared with controls. Parents also perceived a correspondingly greater improvement in their child's pain for those in the acupuncture group compared with the controls (2.3 vs 0.3, P 5 0.04). Adjunctive LA significantly improved pain after pediatric percutaneous kidney biopsies.
Introduction
Acupuncture has long been recognized as effective in treating pain. 55, 60 The 1998 NIH consensus statement endorsed acupuncture for postoperative dental pain 1 ; other groups have described its benefits in procedure pain treatment. 18, 21, 38 Laser acupuncture (LA) is a noninvasive, painless alternative to needles using low-level intensity light. There is evidence for use in myofacial pain 4, 36 and numerous other conditions. 4 In children, LA reduces the intensity and number of migraine headaches, 23 decreases vomiting in postoperative settings, 51 and reduces duration of morphine therapy and hospital stay in neonatal abstinence syndrome infants. 44 Several studies have shown that LA is as effective as traditional acupuncture using needles. When treating musculoskeletal pain, laser stimulation of acupoints is clinically equivalent, and potentially superior, to the same treatment points using needles. 15 Baxter et al. 4 concluded in a systemic review that LA was a viable alternative to other forms of acupuncture point stimulation, including needles. The lack of needles and the safety profile of LA is appealing, especially in pediatrics. This atraumatic treatment reduces the risk of erythema or granuloma formation 41 and presents no bleeding risk. 3 Infection concerns (hepatitis-B, 29 HIV, 58 abscess, and pathogen spread 41 ) also favor laser. 3 Acupuncture is of particular interest in procedural medicine given the time course of action. In studies as early as 1970, acupuncture has shown to reduce pain immediately and provide benefit for hours to days after treatment. This suggests a central mechanism of action rather than solely through local, neural inhibitory mechanisms. 42, 57 Acupuncture is believed to modulate neural signals in central pain-pathways through diverse signaling molecules including opioid peptides, glutamate, endorphins, adenosine, dopamine, serotonin, and dynorphins. 7, 22, 27, 32, 62 Supporting a neuronal mediated mechanism of action, many acupressure points correspond to the location where small nerve bundles penetrate the fascia and nerve bundles that surround major blood vessels. 7 Autonomic nervous system stimulation and somatic signaling have been demonstrated, and the interplay between these systems may further help to facilitate acupuncture effects. 7 Acupoint signals conduct to the brain through the ventrolateral funiculus to activate and deactivate different nuclei and regions. 27, 62 Functional magnetic resonance imaging studies demonstrate specific activations and deactivations in needle 61 and laser 52 treatments. Acupuncture analgesia is the manifestation of integrative processes at different levels of the central nervous system between afferent impulses of pain and signals from acupoints. Although kidney biopsies are integral in the management of nephrology patients, in pediatrics, this procedure carries high levels of anxiety in parents and patients. Sedation medication is used to address anxiety and pain, and nonpharmacologic adjuncts are desired to reduce medication dosage. The kidney biopsy procedure was chosen given high concern for pain, an overnight admission 33, 56 to facilitate completion of postprocedure surveys, and well-defined acupoints associated with kidney energy. 28, 46 The aim of our study was to determine whether the use of LA as an adjuvant therapy with standard sedation medication would reduce patients' overall pain during and after a kidney biopsy.
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Methods

Design
This double-blinded, randomized controlled trial evaluated the effects of LA on pain levels in patients undergoing a kidney biopsy procedure.
Setting and participants
This study enrolled patients aged 7 to 26 years admitted to University of California Benioff Children's Hospital, San Francisco, for a native or transplant kidney biopsy between September 2013 and April 2015. The sample size was determined by power calculation to detect a 1-point difference (9%) 30, 43 on the 0-to 10-point Wong-Baker FACES Pain Rating Scale (WBFPRS), using an SD of 1.5. 40, 47 With a power of 0.8 and an acceptable type I error size of 0.05, 38 patients per group was estimated to achieve significance. Patients requiring repeat biopsies during the study period were allowed to participate in the study with each subsequent biopsy. Patients were not approached for enrollment if an acupuncturist was not available (to ensure blinding) or if the biopsy was scheduled without the knowledge or availability of the study team. Patients were excluded from study enrollment if they were ,7 years, were unable to use the WBFPRS, or required general anesthesia.
Ethical considerations
The study was approved by the Institutional Committee on Human Research. Written informed consent was obtained from patients or parents (as appropriate for age) along with assent for children aged 7 to 17 years. Registered on ClinicalTrials.gov as study NCT01879826.
Randomization
Patients were randomly allocated into the treatment group (TG) or control group (CG) using a 50/50 distribution, random number generator. TG patients received an LA session using treatment acupoints; CG patients received an LA session using different, sham points. The sequentially numbered, sealed envelopes containing the randomization were opened immediately before the acupuncture session and were only viewed by the acupuncturist performing the treatment. Patients presenting for repeat biopsy were randomized without regard to their previous group for blinding integrity.
Blinding
The medical acupuncturist performed the LA session without any procedure staff present. The patient was positioned prone, and acupoints used were not visible to the patient or parent. The laser emitted light and sound that was identical for both groups. The patient then underwent a standard kidney biopsy protocol. The physician performing the acupuncture was not involved in the clinical treatment or pain/anxiety score assessments in any way. Clinical providers, patients, and parents were all blinded to the patient's assigned group.
Protocol
Five licensed, experienced, medical acupuncturists with over a decade of collective acupuncture experience performed 1 session of LA 15 to 30 minutes before the procedure. LA was delivered to all patients using a single, FDA-approved, class 3b, hand-held, Microlight ML830 Acupuncture Laser (Microlight Corporation of America, 2935 Highland Lakes Dr, Missouri City, TX) (Fig. 1) . The gallium-aluminum-arsenide laser, continuous wave mode (wavelength 830 nm), delivers 3 separate, 1-mm diameter, beams in a triangular arrangement. The pulse duration is 33 seconds with 0.99 J and 30 mW of output per beam. 26, 37, 49 A visible red light was added to the beam for safety. All patients were offered protective goggles, and the laser emitted a beep when activated. Acupoints are described according to the 1989 Geneva Standard International Acupuncture Nomenclature, 25 and LA was delivered to gall bladder (GB)-25, bladder (BL)-52, BL-23, BL-22, and BL-21 acupoints in the TG (Fig. 2) . Patients in the CG received LA to different points than did the TG. Points 2 cuns (patient finger breadths) above GB-25, and 2 cuns lateral to BL-52, BL-23, BL-22, and BL-21 were used as the corresponding sham points. Patients in both groups received 33 seconds of active laser to each described point, for a total session length of 5½ minutes.
Kidney biopsies were preformed in the hospital treatment room; all patients underwent the same biopsy protocol regardless of group assignment. Patients were positioned prone or supine as appropriate for native or transplant biopsy, respectively. The area was cleaned and draped in sterile fashion. Local anesthesia (1:1: 0.2 mixture of lidocaine, bupivacaine, and sodium bicarbonate) was given subcutaneously and extending to the kidney capsule. A 3-mm incision was made over the kidney. Using a spring loaded, 16-gauge needle, with direct ultrasound guidance, core biopsies were taken. Additional cores were taken if more tissue was needed for clinical evaluation. A pediatric sedation attending was present throughout the procedure and prescribed pharmacologic sedation. Pressure was held to the site for at least 5 minutes after the procedure.
Data collection
Heart rate, blood pressure, and respiratory rate were measured at baseline and every 15 minutes during the procedure. Sex, weight, age, number of samples, procedure and postprocedure medications, and hospital course were collected from the hospital chart. Patients and their parents were independently surveyed on the pain and anxiety scored with separate survey forms at 2 different time points. Fifteen minutes before the procedure, patients and parents independently assessed baseline-pain and baselineanxiety scores on the preprocedure form. Postprocedure forms were completed 15 minutes to 24 hours after the procedure to assess procedure and postprocedure pain, description of pain, postprocedure anxiety, overall procedure experience ("Better," "Same," or "Worse"), and desire for future laser ("Yes" or "No"). Survey forms used the WBFPRS to assess pain ("0-no hurt" to "10-hurts worst") and a visual analog scale to assess anxiety ("0-not at all" to "10-worst imaginable"). The WBFPRS has been validated in children 20, 39, 54, 59 and was chosen given its simplicity, patient preference, and speed in assessing pain. 10, 39, 54 The anxiety scale 9, 14 was chosen for consistency and given the same feasibility reasons. For further rigor, the study design incorporated as many elements from the IMMPACT recommendations for chronic pain clinical trials as feasible. 16 ,17
Data analysis
All variables were reported as mean with mean standard error or as numbers and percentages. Vital sign and pain/anxiety score changes were calculated as a difference in the procedure to postprocedure values. Differences between the groups were tested using the Mann-Whitney U test and the Fisher exact test. P ,0.05 was considered statistically significant. All statistical analyses were performed with Statistical Package for the Social Sciences 22 (IBM SPSS Statistics Inc, Chicago, IL).
Results
A total of 147 kidney biopsies were performed during the study period, September 2013 to April 2015 (Fig. 3) . Sixty-six patients were not approached for enrollment because of the following reasons: age (n 5 31), general anesthesia (n 5 15), consent was not obtained (n 5 19), or declined to participate (n 5 1). Eleven patients had multiple biopsies. Eighty-one patient encounters were randomized into 2 groups, with 7 excluded from the TG and 5 from the CG because of postprocedure events. These events occurred as a complication of the procedure or later in the hospitalization. Given the potential to confound the assessments of pain and anxiety, they were excluded from the analysis. Biopsy complications necessitating exclusion were active bleeding, large hematoma (hematoma .10 cm in 1 dimension), arterial venous fistula, pressure .15 minutes, enlarging hematoma, or involvement of the pelvic bone. One patient with recurrent hematocolpos pain, one with scrotal edema and anasarca, and one who left against medical advice were excluded. Our procedure complication rate was similar to published rates. 33 Sixty-nine patient encounters were included in the final analysis, 33 in TG and 36 in CG. Baseline characteristics were similar between the groups regarding age, sex, weight, baselineanxiety scores, and previous biopsies ( Table 1) . Baseline pain was significantly higher in the CG with a score of 0.9 (0.3) than in the TG with a score of 0.2 (0.1), P 5 0.046. Both groups shared a similar distribution of native and transplant biopsies, presence of parents and/or a child life specialist, and received similar sedation medication during the procedure with fentanyl, midazolam, and/or ketamine. Child life specialists are professionally certified and trained in working with children in a medical setting. Their participation, as available, is part of standard of care for procedures, like kidney biopsies, at our institution.
Procedure (P 5 0.078) and postprocedural pain (P 5 0.946) scores were similar in both groups with the TG reporting a pain score of 1.9 (0.41) and 1.2 (0.2), respectively, and the CG reporting a pain score of 1.0 (0.23) and 1.4 (0.35), respectively (Fig. 4) . Both groups used a similar amount of acetaminophen postprocedure, with 12.1% (n 5 4) of those in the TG receiving one dose and 11.4% (n 5 4) in the CG receiving one dose, P 5 1.0. Neither group received more than one dose of acetaminophen, nor did any patient use an opioid pain medication after procedure. TG patients reported a significant improvement in the pain score change from procedure to postprocedure when compared with the CG (Fig. 5) . TG patients reported an improvement in pain scores of 0.8 (0.4), and CG patients reported a worsening of pain scores of 20.5 (0.5), P 5 0.044. This was mirrored in the parents' perceptions of the patients' pain. Parents of patients in the TG reported pain improvement with a pain score change of 2.3 (0.8), vs the CG with a pain score change of 0.3 (0.5), P 5 0.04. Patients reported a degree of improvement in their pain of 1.2 points on the pain scale (11%) in the TG vs the CG; parents reported an even larger improvement of 2.0 points on the pain scale (18%).
Patients were observed to have a significant decrease in intraprocedure vital signs including heart rate change of 21.8 (2.7) vs 5.6 (2.4), P 5 0.043, and respiratory rate change of 22.4 (1.1) vs 0.4 (0.9), P 5 0.045, when comparing TG and CG. Expressed as a percent change, the heart rate change was 0.1% vs 7.8% and the respiratory rate change was 28.7% vs 5.4%, respectively (Fig. 6) . The mean arterial pressure change of 23.4 (2.2) vs 2.0 (2.6) in the TG vs CG was not significant, P 5 0.118.
When comparing TG and CG, no significant difference in patient-reported anxiety score changes from before or after the procedure 21.8 (0.5) vs 22.0 (0.5), P 5 0.682, or in parentreported perception of score changes 20.9 (0.4) vs 21.1 (0.4), P 5 0.812, were observed. Regardless of TG vs CG, the majority of patients and their parents desired future LA treatments (90.6% vs 94.3%, P 5 0.292; 93.5% vs 87.9%, P 5 0.625), reported the same or better pain compared with past biopsies (100% vs 95%, P 5 0.697; 86.6% vs 95.7%, P 5 0.488), and believed the patient had received treatment LA (84.4% vs 90.0%, P 5 0.709; 92.9% vs 96.4%, P 5 1.0).
All patients tolerated the LA treatments well without any clinically visible changes to the skin, nor was there any patient distress or negative feedback reported during their hospital course related to the LA.
Discussion
To our knowledge, this is the first blinded randomized controlled trial of procedure pain management with LA in adults or children, and one of the first trials of LA for acute procedure pain. This study showed a clear improvement in self-reported pain scores in the TG vs CG. We believe that this reduction in pain is of clinical significance given the degree in pain improvement, 30, 43 as well as the accompanying vital sign changes, the corresponding parental perceptions of pain improvement, and the overwhelmingly positive experience ratings. The improvements in pain were of a moderate effect size reported by both patients (d 5 0.50) and parents (d 5 0.63). 13 The finding of similar anxiety levels between the groups suggests that LA had a specific effect on pain.
The technical specifications of the LA prescription are important when evaluating efficacy. 26, 37 A systematic review of 18 LA studies noted that only 2 of the 5 high-quality studies used clinically appropriate parameters of at least 10 mW and 0.5 J per point. 4 In a review of placebo-controlled trials, Bjordal et al. 6 recommended that .5 J is needed to treat acute pain. Our laser treatment parameters followed the mean output recommendation from the World Association of Laser Therapy. 5 A study of blood flow velocity in the ophthalmic artery showed that a threshold of 1.3-W/cm 2 power density was important to stimulate effects. 37 It is worth noting that the power density needed to reach an acupoint in the back is likely higher than for the ophthalmic artery, although the exact difference is unknown. Our study's laser prescription (wavelength 830 nm, power output 90 mW, power density 3.8 W/cm 2 , and dose 42 J/cm 2 ) met the highest standard of technical parameters to affect the desired outcomes while balancing safety. Similar device technical parameters have shown to improve headache pain in children. 23 Given safety concerns, the calculated energy density 49 of this study's treatment was 0.042 kJ/cm 2 , much less than the 2.3 to 4.6 kJ/cm 2 energy density treatments showing no adverse skin effects. 34 
Acupoint selection
For patients with nephrolithiasis, Resim et al. 46 used acupoints BL-20, BL-21, BL-22, BL-23, and BL-52 to relieve pain during shockwave lithotripsy. For the same procedure, Rogenhofer et al. 48 used acupoints BL-23, BL-53, large intestine (LI)-4, governor vessel (GV)-20, spleen (SP)-6, and kidney (KI)-3. Recently, a study comparing diclofenac, acupuncture, and acetaminophen on the treatment of renal colic used acupoints BL-21, BL-22, BL-23, BL-24, BL-45, BL-46, BL-47, and BL-48. 28 Of note, none of these studies used LA. Our study used similar points with the addition of GB-25 in hopes of reducing pain during kidney biopsies. This acupuncture point, GB-25, is used to target local lumbar pain specific to the kidney, and it works well with the other acupuncture points to complete the kidney meridian. Although there is some debate in the literature as to appropriate CG treatment for LA studies, we chose to use sham points with an active laser treatment for the CG. This enabled us to maintain blinding as both groups experienced the laser's light and sound activation. The sham points used in this study are unrecognized in the acupuncture field as being related to the kidney meridian or pain. Although the laser used in this study operated a cluster of 3 diodes, care was taken to ensure that there was no overlap of the diode target area between the treatment and sham points. There is no literature comparing the use of single vs cluster diodes for the treatment of kidney meridian pain.
Procedure and acute pain
There are limited data on LA for the treatment of acute pain. For heel-lancing pain in infants, LA was shown to be less effective than oral sucrose. 2 However, this study had numerous limitations including using only one acupoint, no comparison as an adjunct pain tool in the CG, and the low 0.3-J dose per point. The timing of the treatment, ,2 minutes before the procedure, also may have affected the results. Two different studies compared acute neck pain from undefined causes and from whiplash, respectively, 12, 53 with improvement in relative risk of pain when comparing LA with placebo. Soriano et al. 53 reported an improvement in pain in the laser group in both the acute treatment period and reduction in pain recurrence. Although in the whiplash study, no difference was observed in mobility or cervical collar duration. Neither study used LA prophylactically. Fleckenstein et al. 19 showed a reduction in pain using LA for tonsillitis and pharyngitis; however, there was similar pain improvement in both TG and CG. In that study, the sham acupuncture was done to the same acupoints (instead of to sham points). The palpation of the acupoints during this process may have resulted in a similar result for both groups. Again, LA was not used prophylactically. We believe that our study provides additional insight into the therapeutic uses of LA in the management of procedure and acute pain, as well as highlights the differences and importance of pain assessments from patients and parents. 31, 45 
Limitations
Three limitations of this study warrant discussion. First, despite randomization, there was a statistical difference in baseline pain between the groups, with CG reporting higher baseline pain than TG. We did not have detail about the acute or chronic sources of this baseline pain, nor did we have access to any comorbid factors such as depression or anxiety. However, there was no correlation between baseline pain and the postprocedure pain scores (r 5 0.095). Using baseline pain as a covariant in the analysis similarly shows that it was not a significant factor (P 5 0.743). Adjusted pain scores in the TG vs CG remain meaningfully unchanged when using baseline pain as a covariant. Although chronic pain, depression, and anxiety were not used in the statistical analysis for the above reasons, it is well understood that these factors all have a role in modulating pain. 8, 24, 50 Second, given patients and parents evaluated their procedure pain in the postprocedure survey, and not at the biopsy, their response for procedure pain was subject to recall bias. The timing of postprocedure surveys also varied (15 minutes after procedure to the following day) as the patients were not always available at a standard time. Future studies are needed to evaluate the time course of pain relief from LA. Third, the modest sample size may limit the generalizability of these findings.
Our study strengths are also worth emphasizing, which include a rigorous design with strict randomization and concealment of the intervention or control conditions from patients, parents, and providers.
Conclusions
Patients, especially the vulnerable pediatric population, undergo many painful procedures ranging from venipunctures to lumbar punctures and biopsies. Many different, noninvasive, nonpharmacologic interventions have been used successfully to ameliorate pain during these procedures. 11, 35 Our findings from this trial suggest that LA is also an effective therapeutic adjuvant to reduce pain. Laser acupuncture is inexpensive and portable to multiple clinical settings with a negligible risk profile when thoughtful treatment energy dosages and acupoints are chosen.
